ESMO 2021 | MAHOGANY: margetuximab and retifanlimab in HER2+, 1L unresectable/metastatic GEA

Daniel V. Catenacci, MD, of the University of Chicago Medical Center, Chicago, IL, updates on Cohort A of the MAHOGANY study (NCT04082364). Patients enrolled in Cohort A were treated with a chemotherapy-free regimen which investigates margetuximab, HER2-targeting monoclonal antibody in combination with retifanlimab in patients with gastroesophageal cancer (GEA). Cohort A was designed in a 1st-line (1L) setting with patients who were double biomarker selected. This was based on the results of a previous study which evaluated margetuximab in combination with pembrolizumab. The primary end-point was response rates in the first 40 patients evaluable in part 1 of Cohort A. The response rate for the first 40 evaluable patients in cohort A was 53%, the median duration of response was 10.3 months and the best disease control rate was 73%. In addition, the median overall survival was not reached and the median progression-free survival was 6.4 months. Overall, these results are very promising as they demonstrate the highest response rates observed with a chemotherapy-free approach in this patient population. Part 2 of the study with cohort A will now proceed, as the response rates met the required benchmark. This interview took place during the European Society for Medical Oncology (ESMO) 2021 congress.